NPS+ Renal Cell Carcinoma (EU5) 2018
|NPS+:腎細胞癌 (EU5個國家) NPS+ Renal Cell Carcinoma (EU5) 2018|
|出版日期: 2018年02月01日||內容資訊: 英文||
稱本報告提供EU5個國家的癌症專門醫生150名為對象下面調查結果為基礎，腎細胞癌治療藥的領導品牌調查分析，客戶的忠誠度(權利金)的NPS (淨推薦值) 指標相關的系統性資訊。
Why are some EU5 RCC brands standing out more than others?
There are various options available to EU5 oncologists to treat renal cell carcinoma (RCC). Clearly some of these options are achieving greater levels of loyalty and satisfaction than others - but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors?
NPS+ RCC (EU5) gives a unique insight into the overall brand health of 9 leading treatments for RCC currently being used in Europe. 150 oncologists were surveyed on key issues including brand messaging, prescribing behaviour and satisfaction levels. The results provide valuable insight for brand marketers seeking new ways to stand out.
NPS+ RCC (EU5) offers valuable insight into brand loyalty from the perspective of those currently prescribing treatments for RCC to patients. You'll discover:
We surveyed 150 EU-based oncologists chosen from the largest community of validated physicians in the world. We conducted the survey between January 10-20, 2018.
NPS is a customer loyalty metric developed by (and a registered trademark of) Fred Reichheld, Bain & Company, and Satmetrix. It was introduced by Reichheld in his 2003 Harvard Business Review article One Number You Need to Grow.
NPS measures overall brand satisfaction and loyalty by asking one simple question:
Responses - given on a scale of 0 (not at all likely) to 10 (extremely likely)-are used to classify respondents into 3 categories:
The percentage of detractors - the percentage of promoters = NPS.
For example, 25% Promoters, 55% Passives and 20% Detractors give you an NPS of +5.
NPS can range from -100 (everybody is a Detractor) to +100 (everybody is a Promoter). The higher the score the healthier the brand.
NPS+ turns your Net Promoter Score into actionable information by answering key questions about brand loyalty.
Each NPS+ report examines doctors' relationships with the brands used to treat a major disease area-measuring brand loyalty and showing you how it affects your market share. NPS+ also examines "brand DNA", revealing in doctors' own words what brands mean to them.
Instead of one simple metric, NPS+ gives you a detailed picture of brand health that highlights areas for improvement, and helps you see exactly what steps you need to take next.
At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.